| SEC F | Form 4 |
|-------|--------|
|-------|--------|

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden

0.5

hours per response:

|  | Check this box if no longer subject to<br>Section 16. Form 4 or Form 5<br>obligations may continue. See<br>Instruction 1(b). |
|--|--|
|--|--|

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* ONSI DOUGLAS E (Last) (First) (Middle) C/O LEAP THERAPEUTICS, INC. |         |       | 2. Issuer Name and Ticker or Trading Symbol LEAP THERAPEUTICS, INC. [LPTX] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)   |  |  |  |  |  |
|---|---------|-------|--|---|--|--|--|--|--|
|   |         |       | 3. Date of Earliest Transaction (Month/Day/Year)<br>04/18/2018             | Director     X     10% Owner       X     Officer (give title<br>below)     Other (specify<br>below)       CFO, GC Treasurer & Secretary |  |  |  |  |  |
| 47 THORNDIKE STREET SUITE B1-1  |         |       | 4. If Amendment, Date of Original Filed (Month/Day/Year)                   | 6. Individual or Joint/Group Filing (Check Applicable Line)   |  |  |  |  |  |
| (Street)<br>CAMBRIDGE   | MA      | 02141 |  | X Form filed by One Reporting Person<br>Form filed by More than One Reporting<br>Person   |  |  |  |  |  |
| (City)  | (State) | (Zip) | Derivative Securities Acquired, Disposed of, or Bene                       |   |  |  |  |  |  |

| 1. Title of Security (Instr. 3) | Date | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | Transaction<br>Code (Instr. |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 an<br>5) |               |       | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|------|---|-----------------------------|---|--|---------------|-------|---|---|---|
|                                 |      |   | Code                        | v | Amount   | (A) or<br>(D) | Price | Transaction(s)<br>(Instr. 3 and 4)  |   | (11501.4)   |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | 5. Numb<br>of<br>Derivati<br>Securiti<br>Acquire<br>(A) or<br>Dispose<br>of (D) (II<br>3, 4 and | ve<br>es<br>d<br>ed<br>nstr. | Expiration Da       | Expiration Date of Securities (Month/Day/Year) Underlying Deriv |   | nderlying Derivative Security<br>ecurity (Instr. 3 and (Instr. 5) |     | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|------------------------------|---|---|------------------------------|---------------------|---|---|---|-----|--|--|--|
|   |   |  |   | Code                         | v | (A)   | (D)                          | Date<br>Exercisable | Expiration<br>Date  | Title   | Amount or<br>Number of<br>Shares                                  |     |  |  |  |
| Stock<br>Option<br>(Right to<br>Buy)                | \$7.66  | 04/18/2018                                 |   | A                            |   | 50,000  |                              | (1)                 | 04/17/2028  | Common<br>Stock,<br>\$0.001<br>par value<br>per share | 50,000 <sup>(1)</sup>   | \$0 | 50,000   | D  |  |

Explanation of Responses:

1. The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 48 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of April 18, 2018, the Vesting Start Date.

| <u>/s</u> | <u>/ Douglas E. Onsi</u> |        |
|-----------|--------------------------|--------|
| **        | Signature of Reporting   | Person |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

04/20/2018 Date